CrystalGenomics, Inc.

KOSDAQ 083790.KQ

CrystalGenomics, Inc. EBT Margin for the year ending December 31, 2023: -1,048.48%

CrystalGenomics, Inc. EBT Margin is -1,048.48% for the year ending December 31, 2023. EBT Ratio (Earnings Before Tax Ratio) is the fraction of earnings before taxes to total revenue, indicating the company's profitability before the impact of tax expenses.

CrystalGenomics, Inc. EBT Margin for the year ending December 31, 2021 was -36.85%, a 20.50% change year over year.
CrystalGenomics, Inc. EBT Margin for the year ending December 31, 2020 was -46.36%.

Key data

Date	EBT Margin	Net Income Margin	EBITDA Margin	EBIT Margin

KOSDAQ: 083790.KQ

CrystalGenomics, Inc.

CEO	Dr. Joong-Myung Cho Ph.D.
IPO Date	Jan. 6, 2006
Location	South Korea
Headquarters	Tower A, Korea Bio Park
Employees	65
Sector	Healthcare
Industries Biotechnology Clinical Trials Personal Care Pharmaceuticals Plastics Vaccines

Description

CrystalGenomics, Inc., a biopharmaceutical company, discovers and develops structural chemoproteiomics-based drugs in Korea. Its lead development candidate is NSAID (CG100649), which is a tissue specific anti-inflammatory agent with cardiovascular, gastrointestinal, and renal safety profiles that has completed Phase IIa clinical trial. The company's drug candidates also include CG200745, a histone deacetylase inhibitor for cancer, which is in Phase I clinical trial; and CG400549, an antibiotic candidate for methicillin resistant staphylococcus aureus and vancomycin resistant staphylococcus aureus, which is in Phase I clinical trial. In addition, it offers cloning, expression, purification, and characterization of proteins of interest; and assay and structure services. The company has drug discovery collaborations with AstraZeneca, Daiichi-Sankyo, SBI-Biotech, Carna Biosciences, Yuyu Pharma, AmorePacific, Hanmi Pharmaceuticals, and ProQuest Investments. CrystalGenomics, Inc. was founded in 2000 and is headquartered in Seongnam, South Korea.

Key trends

Past 5 years